SPINAL CORD INJURY RESEARCH AND ADVOCACY| Published: July 18, 2018
Worldwide licensing agreement made on peptide developed in Silver laboratory at Case Western Reserve University
VANCOUVER, British Columbia, July 18, 2018 (GLOBE NEWSWIRE) — NervGen Pharma Corp. (“NervGen”), in Vancouver, and Case Western Reserve University (“Case Western Reserve”) in Cleveland have entered into an exclusive worldwide licensing agreement to research, develop and commercialize a patented technology with potential to bring new therapies for spinal cord injury and other conditions associated with nerve damage.
The technology was developed in the laboratory of Dr. Jerry Silver, a leading spinal cord injury and regenerative medicine researcher at Case Western Reserve. Dr. Silver’s research has implicated protein tyrosine phosphatase sigma (PTPs) as a key neural receptor which inhibits nerve regeneration through regions of scarring in spinal cord injury and other medical conditions.
Targeted treatment against PTPs with an agent known as ISP promoted regeneration of damaged nerves and functional improvement in animal models for various medical conditions. A series of receptor antagonists that can be delivered systemically have been identified including an analogue of ISP that is ready for clinical development.
Posted on July 18, 2018 by christalpowell
Read the Full Article at Globe Newswire.